ArticleBritish journal of clinical pharmacology2010
Effectiveness, safety and cost of drug substitution in hypertension.
Article in British journal of clinical pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings.European journal of clinical pharmacology · 2019Pooled it
- A retrospective analysis of e-prescriptions for non-communicable diseases on a telehealth platform in Malaysia.BMC health services research · 2024Observational
- An exploration of factors influencing the selection of generic and innovator medicines in Saudi Arabia using an observational cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.Archives of osteoporosis · 2022Observational
- Nature and frequency of prescription modifications in community pharmacies: A nationwide study in the Netherlands.British journal of clinical pharmacology · 2021Article
- Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Review
- Potential Clinical and Economic Impact of Switching Branded Medications to Generics.American journal of therapeutics · 2017Review
- Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.BMJ (Clinical research ed.) · 2017Article
- Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries.Cardiology clinics · 2017Review
- The Effect of Dongeui Qigong for Prehypertension and Mild Essential Hypertension.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Blood Pressure Management in Intracranial Hemorrhage: Current Challenges and Opportunities.Current treatment options in cardiovascular medicine · 2016Article
- Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland.BMC research notes · 2015Article
- A retrospective analysis of drug-related problems documented in a national database.International journal of clinical pharmacy · 2013Article
- A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.BMC pharmacology & toxicology · 2013Review
- Cluster randomized trials of prescription medicines or prescribing policy: public and general practitioner opinions in Scotland.British journal of clinical pharmacology · 2012Article
- Editors' pick 2010.British journal of clinical pharmacology · 2011Article
- Generic and therapeutic substitutions: are they always ethical in their own terms?Pharmacy world & science : PWS · 2010Review
- From NCE to NICE: the role of pharmacoeconomics.British journal of clinical pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cost-containment measures in healthcare provision include the implementation of therapeutic and generic drug substitution strategies in patients whose condition is already well controlled with pharmacotherapy. Treatment for hypertension is frequently targeted for such measures. However, drug acquisition costs are only part of the cost-effectiveness equation, and a variety of other factors need to be taken into account when assessing the impact of switching antihypertensives. From the clinical perspective, considerations include maintenance of an appropriate medication dose during the switching process; drug equivalence in terms of clinical effectiveness; and safety issues, including the diverse adverse-event profiles of available alternative drugs, differences in the 'inactive' components of drug formulations and the quality of generic formulations. Patients' adherence to and persistence with therapy may be negatively influenced by switching, which will also impact on treatment effectiveness. From the economic perspective, the costs that are likely to be incurred by switching antihypertensives include those for additional clinic visits and laboratory tests, and for hospitalization if required to address problems arising from adverse events or poorly controlled hypertension. Indirect costs and the impact on patients' quality of life also require assessment. Substitution strategies for antihypertensives have not been tested in large outcome trials and there is little available clinical or economic evidence on which to base decisions to switch drugs. Although the cost of treatment should always be considered, careful assessment of the human and economic costs and benefits of antihypertensive drug substitution is required before this practice is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.